• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD

Lung Cancer Drug Pipeline Update 2015

  • ID: 1197058
  • June 2015
  • Region: Global
  • Bioseeker

Non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) comprises over 95% of all lung cancers. High unmet needs still persist for this tumor type and despite two decades of extensive R&D and chemotherapy use, the median overall survival of NSCLC patient’s remains below 12 months. Mesothelioma is rarer, although incidence is expected to increase in the coming years in Europe and Japan given the heavy use of asbestos in the 1970s and long latency period of the disease.
There are today 479 companies plus partners developing 661 lung cancer drugs in 801 developmental projects in cancer. In addition, there are 11 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 259 drugs. Lung Cancer Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 377 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer. To date 358 out of the 360 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational READ MORE >

Note: Product cover images may vary from those shown

Delivery Format: Desktop App plus Online Access to Updates (One Year)

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown


Our Clients

Varian Medical Systems, Inc. Bayer AG Bristol-Myers Squibb Amgen Inc. Almac Diagnostics Group Boston Biomedical Inc.